Granite Point Capital Management L.P. Lowers Holdings in Dermira, Inc. (DERM)

Granite Point Capital Management L.P. cut its position in Dermira, Inc. (NASDAQ:DERM) by 0.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 38,033 shares of the biopharmaceutical company’s stock after selling 117 shares during the quarter. Granite Point Capital Management L.P. owned about 0.09% of Dermira worth $1,108,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of DERM. BNP Paribas Arbitrage SA raised its stake in shares of Dermira by 2,220.7% in the second quarter. BNP Paribas Arbitrage SA now owns 4,154 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 3,975 shares during the period. SG Americas Securities LLC raised its stake in shares of Dermira by 66.8% in the second quarter. SG Americas Securities LLC now owns 5,503 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 2,203 shares during the period. KCG Holdings Inc. bought a new stake in shares of Dermira in the first quarter valued at $215,000. Legal & General Group Plc raised its stake in shares of Dermira by 16.3% in the first quarter. Legal & General Group Plc now owns 6,861 shares of the biopharmaceutical company’s stock valued at $236,000 after buying an additional 963 shares during the period. Finally, RidgeWorth Capital Management LLC bought a new stake in shares of Dermira in the first quarter valued at $297,000. Hedge funds and other institutional investors own 97.56% of the company’s stock.

WARNING: This story was first published by Markets Daily and is the sole property of of Markets Daily. If you are viewing this story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The original version of this story can be accessed at https://www.themarketsdaily.com/2017/09/13/granite-point-capital-management-l-p-lowers-holdings-in-dermira-inc-derm.html.

In related news, CEO Thomas G. Wiggans sold 5,000 shares of Dermira stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $29.06, for a total transaction of $145,300.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Eugene A. Bauer sold 2,500 shares of Dermira stock in a transaction on Tuesday, June 20th. The shares were sold at an average price of $30.01, for a total value of $75,025.00. The disclosure for this sale can be found here. Insiders have sold 11,700 shares of company stock worth $337,537 over the last quarter. 13.30% of the stock is owned by company insiders.

Dermira, Inc. (NASDAQ DERM) traded up 0.95% during mid-day trading on Wednesday, hitting $25.43. The company had a trading volume of 35,949 shares. The firm’s 50 day moving average is $24.87 and its 200 day moving average is $29.77. The company’s market capitalization is $1.06 billion. Dermira, Inc. has a 52 week low of $21.35 and a 52 week high of $38.75.

Dermira (NASDAQ:DERM) last released its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.93) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.89) by ($0.04). The company had revenue of $1.07 million for the quarter, compared to analysts’ expectations of $1.00 million. Dermira had a negative net margin of 408.50% and a negative return on equity of 31.66%. On average, equities research analysts predict that Dermira, Inc. will post ($4.20) EPS for the current year.

Several analysts have issued reports on DERM shares. Needham & Company LLC restated a “buy” rating and issued a $46.00 target price on shares of Dermira in a research note on Tuesday, July 18th. BidaskClub upgraded Dermira from a “hold” rating to a “buy” rating in a research note on Tuesday, June 27th. Mizuho decreased their price objective on Dermira from $42.00 to $40.00 and set a “buy” rating on the stock in a research note on Thursday, May 25th. Zacks Investment Research upgraded Dermira from a “sell” rating to a “hold” rating in a research note on Thursday, August 17th. Finally, Evercore ISI initiated coverage on Dermira in a research note on Thursday, June 29th. They set an “outperform” rating and a $48.00 price objective on the stock. Four equities research analysts have rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company. Dermira presently has a consensus rating of “Hold” and a consensus target price of $44.40.

Dermira Profile

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

Want to see what other hedge funds are holding DERM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dermira, Inc. (NASDAQ:DERM).

Institutional Ownership by Quarter for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply